GB2632571A - 5-pyridine-1H-indazole compound, pharmaceutical composition, and use - Google Patents

5-pyridine-1H-indazole compound, pharmaceutical composition, and use Download PDF

Info

Publication number
GB2632571A
GB2632571A GB2415076.5A GB202415076A GB2632571A GB 2632571 A GB2632571 A GB 2632571A GB 202415076 A GB202415076 A GB 202415076A GB 2632571 A GB2632571 A GB 2632571A
Authority
GB
United Kingdom
Prior art keywords
acid
compound
calculated
dmso
mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB2415076.5A
Other languages
English (en)
Other versions
GB202415076D0 (en
Inventor
Li Zhiyu
Bian Jinlei
Hu Tianxing
Liu Mai
Song Jiaxing
Qiu Zhixia
Wu Hongqian
Xu Xi
Wang Jubo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Publication of GB202415076D0 publication Critical patent/GB202415076D0/en
Publication of GB2632571A publication Critical patent/GB2632571A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB2415076.5A 2022-08-24 2022-11-22 5-pyridine-1H-indazole compound, pharmaceutical composition, and use Pending GB2632571A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202211018173.7A CN115353508B (zh) 2022-08-24 2022-08-24 5-吡啶-1h-吲唑类化合物、药物组合物和应用
PCT/CN2022/133423 WO2024040768A1 (zh) 2022-08-24 2022-11-22 5-吡啶-1h-吲唑类化合物、药物组合物和应用

Publications (2)

Publication Number Publication Date
GB202415076D0 GB202415076D0 (en) 2024-11-27
GB2632571A true GB2632571A (en) 2025-02-12

Family

ID=84003747

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2415076.5A Pending GB2632571A (en) 2022-08-24 2022-11-22 5-pyridine-1H-indazole compound, pharmaceutical composition, and use

Country Status (8)

Country Link
US (1) US20260070889A1 (https=)
JP (1) JP2025515926A (https=)
KR (1) KR20250007528A (https=)
CN (1) CN115353508B (https=)
AU (1) AU2022475622A1 (https=)
CA (1) CA3255205A1 (https=)
GB (1) GB2632571A (https=)
WO (1) WO2024040768A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115353508B (zh) * 2022-08-24 2023-07-21 中国药科大学 5-吡啶-1h-吲唑类化合物、药物组合物和应用
CN115785071B (zh) * 2023-01-09 2024-01-26 中国药科大学 3-乙炔基-5-（1h-1,2,3-三唑-4-基）-1h-吲唑类化合物及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199511A1 (en) * 2001-12-13 2003-10-23 Qun Li Kinase inhibitors
WO2012078777A1 (en) * 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
US20160009696A1 (en) * 2013-03-04 2016-01-14 Michael Miller Compounds inhibiting leucine-rich repeat kinase enzyme activity
US20160009682A1 (en) * 2013-03-04 2016-01-14 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN105958990A (zh) * 2016-05-24 2016-09-21 内蒙古包钢钢联股份有限公司 光电接近开关保护装置
CN106032359A (zh) * 2015-03-09 2016-10-19 复旦大学 吲唑类化合物及其制备方法和用途
CN113164476A (zh) * 2018-09-28 2021-07-23 代表亚利桑那大学的亚利桑那校董会 Dyrk1/clk的小分子抑制剂及其用途
CN115353508A (zh) * 2022-08-24 2022-11-18 中国药科大学 5-吡啶-1h-吲唑类化合物、药物组合物和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102595899A (zh) * 2009-08-10 2012-07-18 埃皮瑟瑞克斯有限公司 作为wnt/b-联蛋白信号传导途径抑制剂的吲唑及其治疗用途
PH12017500997A1 (en) * 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
MX380092B (es) * 2015-11-06 2025-03-11 Samumed Llc Tratamiento de la osteoartritis.
WO2019241540A1 (en) * 2018-06-15 2019-12-19 Samumed, Llc Indazole containing macrocycles and therapeutic uses thereof
US20230000842A1 (en) * 2019-01-17 2023-01-05 Samumed, Llc Methods of treating cartilage disorders through inhibition of clk and dyrk
WO2022012058A1 (zh) * 2020-07-16 2022-01-20 江苏凯迪恩医药科技有限公司 稠环化合物及其中间体、制备方法和应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199511A1 (en) * 2001-12-13 2003-10-23 Qun Li Kinase inhibitors
WO2012078777A1 (en) * 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
US20160009696A1 (en) * 2013-03-04 2016-01-14 Michael Miller Compounds inhibiting leucine-rich repeat kinase enzyme activity
US20160009682A1 (en) * 2013-03-04 2016-01-14 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN106032359A (zh) * 2015-03-09 2016-10-19 复旦大学 吲唑类化合物及其制备方法和用途
CN105958990A (zh) * 2016-05-24 2016-09-21 内蒙古包钢钢联股份有限公司 光电接近开关保护装置
CN113164476A (zh) * 2018-09-28 2021-07-23 代表亚利桑那大学的亚利桑那校董会 Dyrk1/clk的小分子抑制剂及其用途
CN115353508A (zh) * 2022-08-24 2022-11-18 中国药科大学 5-吡啶-1h-吲唑类化合物、药物组合物和应用

Also Published As

Publication number Publication date
KR20250007528A (ko) 2025-01-14
JP2025515926A (ja) 2025-05-20
CN115353508A (zh) 2022-11-18
WO2024040768A1 (zh) 2024-02-29
GB202415076D0 (en) 2024-11-27
CN115353508B (zh) 2023-07-21
US20260070889A1 (en) 2026-03-12
CA3255205A1 (en) 2025-03-27
AU2022475622A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
ES2548228T3 (es) Derivados de bencimidazol e imidazopiridina como moduladores de canal de sodio
CA2913840C (en) Compounds with anti-cancer activity
NO323952B1 (no) Substituerte indoler for modulering av NFκB-aktivitet, fremgangsmate for fremstilling, legemiddel omfattende disse, deres anvendelse og en fremgangsmate for fremstilling av et legemiddel.
NZ231588A (en) Quinazoline-4-one derivatives, medicaments
TW201105326A (en) Diamino heterocyclic carboxamide compound
CN112851663B (zh) 一种并杂环化合物及其用途
CA3063111A1 (en) Histone deacetylases (hdacs) inhibitors
JPWO2010007944A1 (ja) 含窒素二環性複素環化合物
GB2632571A (en) 5-pyridine-1H-indazole compound, pharmaceutical composition, and use
WO2019154395A1 (zh) 四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途
WO2024235013A1 (zh) 一种含吲唑基的羟肟酸衍生物及其应用
US20220402867A1 (en) Sulfo-substituted biaryl compound or salt thereof, preparation method therefor, and use thereof
EP4031245A1 (en) Heteroaryl plasma kallikrein inhibitors
CA2958741A1 (en) Quinazoline derivatives
EA010392B1 (ru) Производные имидазолов, способ их получения и их применение в качестве лекарственного средства
WO2005080392A1 (ja) ピラゾロキノロン誘導体およびその用途
WO2021063276A1 (zh) 大环类衍生物及其制备方法和用途
CN108069954A (zh) 含no供体的喹唑啉酮化合物
CN104876849B (zh) 一种吲哚衍生物及其用途
CN107501279B (zh) 呋喃并喹啉二酮类化合物及其医药用途
TWI909603B (zh) 用於預防或治療癌症或腫瘤之新穎化合物及包含該化合物的醫藥組成物
CN107311933B (zh) 一类苯并咪唑衍生物，及其制备方法和用途
EP1270569A1 (en) Substituted tryptophan derivatives
CN117088874A (zh) 二酰甘油激酶抑制剂及其用途
CN106632065B (zh) 苯并咪唑类化合物及其应用